Cargando…

The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease that affects the central nervous system. A recent study showed that interaction between the immune system and the gut microbiota plays a crucial role in the development of MS. This review reports the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Schepici, Giovanni, Silvestro, Serena, Bramanti, Placido, Mazzon, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923550/
https://www.ncbi.nlm.nih.gov/pubmed/31512505
http://dx.doi.org/10.1177/0963689719873890
_version_ 1783481555409174528
author Schepici, Giovanni
Silvestro, Serena
Bramanti, Placido
Mazzon, Emanuela
author_facet Schepici, Giovanni
Silvestro, Serena
Bramanti, Placido
Mazzon, Emanuela
author_sort Schepici, Giovanni
collection PubMed
description Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease that affects the central nervous system. A recent study showed that interaction between the immune system and the gut microbiota plays a crucial role in the development of MS. This review reports the clinical studies carried out in recent years that aimed to evaluate the composition of the microbiota in patients with relapsing–remitting MS (RR-MS). We also report what is available in the literature regarding the effectiveness of fecal microbiota transplantation and the role of the diet in restoring the intestinal bacterial population. Studies report that patients with RR-MS have a microbiota that, compared with healthy controls, has higher amounts of Pedobacteria, Flavobacterium, Pseudomonas, Mycoplana, Acinetobacter, Eggerthella, Dorea, Blautia, Streptococcus and Akkermansia. In contrast, MS patients have a microbiota with impoverished microbial populations of Prevotella, Bacteroides, Parabacteroides, Haemophilus, Sutterella, Adlercreutzia, Coprobacillus, Lactobacillus, Clostridium, Anaerostipes and Faecalibacterium. In conclusion, the restoration of the microbial population in patients with RR-MS appears to reduce inflammatory events and the reactivation of the immune system.
format Online
Article
Text
id pubmed-6923550
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-69235502020-01-03 The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials Schepici, Giovanni Silvestro, Serena Bramanti, Placido Mazzon, Emanuela Cell Transplant Reviews Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease that affects the central nervous system. A recent study showed that interaction between the immune system and the gut microbiota plays a crucial role in the development of MS. This review reports the clinical studies carried out in recent years that aimed to evaluate the composition of the microbiota in patients with relapsing–remitting MS (RR-MS). We also report what is available in the literature regarding the effectiveness of fecal microbiota transplantation and the role of the diet in restoring the intestinal bacterial population. Studies report that patients with RR-MS have a microbiota that, compared with healthy controls, has higher amounts of Pedobacteria, Flavobacterium, Pseudomonas, Mycoplana, Acinetobacter, Eggerthella, Dorea, Blautia, Streptococcus and Akkermansia. In contrast, MS patients have a microbiota with impoverished microbial populations of Prevotella, Bacteroides, Parabacteroides, Haemophilus, Sutterella, Adlercreutzia, Coprobacillus, Lactobacillus, Clostridium, Anaerostipes and Faecalibacterium. In conclusion, the restoration of the microbial population in patients with RR-MS appears to reduce inflammatory events and the reactivation of the immune system. SAGE Publications 2019-09-12 2019-12 /pmc/articles/PMC6923550/ /pubmed/31512505 http://dx.doi.org/10.1177/0963689719873890 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Reviews
Schepici, Giovanni
Silvestro, Serena
Bramanti, Placido
Mazzon, Emanuela
The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
title The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
title_full The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
title_fullStr The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
title_full_unstemmed The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
title_short The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
title_sort gut microbiota in multiple sclerosis: an overview of clinical trials
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923550/
https://www.ncbi.nlm.nih.gov/pubmed/31512505
http://dx.doi.org/10.1177/0963689719873890
work_keys_str_mv AT schepicigiovanni thegutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials
AT silvestroserena thegutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials
AT bramantiplacido thegutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials
AT mazzonemanuela thegutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials
AT schepicigiovanni gutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials
AT silvestroserena gutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials
AT bramantiplacido gutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials
AT mazzonemanuela gutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials